[A17-30] Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07
Last updated 17.08.2017
Commission awarded on 11.07.2017 by the Federal Joint Committee (G-BA).
Skin and hair
Adults with moderate to severe plaque psoriasis
Indication of considerable added benefit now also for patients who are eligible for systemic and/or phototherapy
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A17-07||Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V||Commission completed|